A significant proportion of patients, however, have no initial response (primary non-response) or eventual loss of response (secondary loss of response) to therapy.
Response duration was defined as the interval from anemia response to loss of response, change of therapy, or death.
In all, we increased propofol effect-site concentration (Ce) until loss of response to the ARM occurred.
Retrospective life chart data were evaluated to investigate the incidence of loss of response.
Background: The loss of response to antidepressant drugs is not an uncommon phenomenon.
It is thought that a majority of the cases of secondary loss of response are due to the formation of antibodies against the therapeutic agent, termed immunogenicity.
Inadequate infliximab (IFX) drug exposure remains a clinical challenge and leads to high loss of response rates and therapy failure in inflammatory bowel disease (IBD).
However, a proportion of patients have eventual loss of response due to immunogenicity against the biologic, which can be prevented by combination therapy with immunomodulators (IM).
Qiu, Y. et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFalpha dose intensification in Crohn's disease.
Standard infliximab maintenance dosing of 5 mg/kg every 8 weeks may be inadequate to consistently achieve sufficient drug exposure to minimize loss of response or treatment failure in pediatric Crohn's disease (CD).
Method: I describe 15 cases who had a loss of response to repeated trials of antidepressants before developing a chronic and severe, refractory depression.
